Omnicell Company Profile (NASDAQ:OMCL)

About Omnicell (NASDAQ:OMCL)

Omnicell logoOmnicell, Inc. provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence. The Automation and Analytics segment is engaged in the design, manufacturing, selling and servicing of medication and supply dispensing systems, pharmacy inventory management systems and related software. The Medication Adherence segment includes the development, manufacturing and selling of consumable medication blister cards, packaging equipment, medication synchronization platform, and ancillary products and services. Its products are used to manage medication administration outside of the hospital setting and include medication adherence products sold under the brand name MTS, Surgichem, SureMed and the Omnicell brand.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Software & Technology Services
  • Sub-Industry: Health Care Technology
  • Symbol: NASDAQ:OMCL
  • CUSIP: 68213N10
  • Web:
  • Market Cap: $1.85396 billion
  • Outstanding Shares: 37,454,000
Average Prices:
  • 50 Day Moving Avg: $50.04
  • 200 Day Moving Avg: $43.64
  • 52 Week Range: $30.35 - $52.70
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 40.24
  • P/E Growth: 2.26
Sales & Book Value:
  • Annual Revenue: $680.15 million
  • Price / Sales: 2.73
  • Book Value: $12.00 per share
  • Price / Book: 4.13
  • EBIDTA: $42.68 million
  • Net Margins: -1.14%
  • Return on Equity: 0.41%
  • Return on Assets: 0.19%
  • Debt-to-Equity Ratio: 0.41%
  • Current Ratio: 1.40%
  • Quick Ratio: 1.01%
  • Average Volume: 240,408 shs.
  • Beta: 0.67
  • Short Ratio: 20.31

Frequently Asked Questions for Omnicell (NASDAQ:OMCL)

What is Omnicell's stock symbol?

Omnicell trades on the NASDAQ under the ticker symbol "OMCL."

How were Omnicell's earnings last quarter?

Omnicell, Inc. (NASDAQ:OMCL) released its quarterly earnings data on Thursday, July, 27th. The company reported $0.02 EPS for the quarter, meeting the consensus estimate of $0.02. The company earned $180.90 million during the quarter, compared to the consensus estimate of $174.08 million. Omnicell had a positive return on equity of 0.41% and a negative net margin of 1.14%. The firm's revenue for the quarter was up 4.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.38 EPS. View Omnicell's Earnings History.

When will Omnicell make its next earnings announcement?

Omnicell is scheduled to release their next quarterly earnings announcement on Wednesday, October, 25th 2017. View Earnings Estimates for Omnicell.

What guidance has Omnicell issued on next quarter's earnings?

Omnicell updated its FY17 earnings guidance on Thursday, July, 27th. The company provided EPS guidance of $1.22-$1.34 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.28. The company issued revenue guidance of $720-$740 million, compared to the consensus revenue estimate of $729.63 million.Omnicell also updated its Q3 guidance to $0.38-$0.45 EPS.

Where is Omnicell's stock going? Where will Omnicell's stock price be in 2017?

7 brokerages have issued 12 month target prices for Omnicell's shares. Their predictions range from $40.00 to $67.00. On average, they expect Omnicell's share price to reach $51.57 in the next twelve months. View Analyst Ratings for Omnicell.

What are analysts saying about Omnicell stock?

Here are some recent quotes from research analysts about Omnicell stock:

  • 1. Cantor Fitzgerald analysts commented, "Omnicell announced today that White River Health System in North Central Arkansas selected the company’s automated medication management solutions as well as their pharmacy management software." (7/25/2017)
  • 2. According to Zacks Investment Research, "Over the last one month, Omnicell is trading below the Zacks Categorized Medical Information Systems industry. We are concerned about the company’s increasing cost of production and integration expenses. The company’s last reported first quarter report was also disappointing with year-over-year decline in both earnings and revenues. The escalating costs continue to dent margin performance. Weak hospital spending trends and tough competition also pose threats. Yet, the market is optimistic on the growing significance of medication non-adherence where Omnicell is making substantial expansion. The company is also progressing well with its three-pronged growth strategy. We are particularly looking forward to the launch of the XT Series in the quarter which should boost revenue and profitability down the line." (7/4/2017)

Who are some of Omnicell's key competitors?

Who are Omnicell's key executives?

Omnicell's management team includes the folowing people:

  • Randall A. Lipps, Chairman of the Board, President, Chief Executive Officer
  • Peter J. Kuipers, Chief Financial Officer, Executive Vice President
  • Daniel S. Johnston, Executive Vice President, Chief Legal and Administrative Officer
  • J. Christopher Drew, Executive Vice President of Sales and Marketing for North American Automation
  • Nhat H. Ngo, Executive Vice President - Strategy and Business Development
  • Robin Gene Seim, Executive Vice President, Global Automation and Medication Adherence
  • Jorge R. Taborga, Executive Vice President - Engineering and Integration Management Office
  • James T. Judson, Lead Independent Director
  • Joanne B. Bauer, Independent Director
  • Vance B. Moore, Independent Director

Who owns Omnicell stock?

Omnicell's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (12.32%), Vanguard Group Inc. (5.18%), Conestoga Capital Advisors LLC (4.32%), Dimensional Fund Advisors LP (4.22%), Oak Ridge Investments LLC (4.13%) and Daruma Capital Management LLC (3.61%). Company insiders that own Omnicell stock include Dan S Johnston, Gary S Petersmeyer, J Christopher Drew, James T Judson, Jorge R Taborga, Nhat H Ngo, Peter J Kuipers, Randall A Lipps, Robin Gene Seim and Sara J White. View Institutional Ownership Trends for Omnicell.

Who sold Omnicell stock? Who is selling Omnicell stock?

Omnicell's stock was sold by a variety of institutional investors in the last quarter, including Teachers Advisors LLC, Dimensional Fund Advisors LP, Daruma Capital Management LLC, Wells Fargo & Company MN, Systematic Financial Management LP, UBS Asset Management Americas Inc., King Luther Capital Management Corp and Strs Ohio. Company insiders that have sold Omnicell stock in the last year include Dan S Johnston, Gary S Petersmeyer, J Christopher Drew, James T Judson, Jorge R Taborga, Peter J Kuipers, Randall A Lipps, Robin Gene Seim and Sara J White. View Insider Buying and Selling for Omnicell.

Who bought Omnicell stock? Who is buying Omnicell stock?

Omnicell's stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Principal Financial Group Inc., First Light Asset Management LLC, Russell Investments Group Ltd., Rice Hall James & Associates LLC, BlackRock Inc., Westwood Holdings Group Inc. and Conestoga Capital Advisors LLC. View Insider Buying and Selling for Omnicell.

How do I buy Omnicell stock?

Shares of Omnicell can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Omnicell's stock price today?

One share of Omnicell stock can currently be purchased for approximately $49.50.

MarketBeat Community Rating for Omnicell (NASDAQ OMCL)
Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  227 (Vote Outperform)
Underperform Votes:  129 (Vote Underperform)
Total Votes:  356
MarketBeat's community ratings are surveys of what our community members think about Omnicell and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Omnicell (NASDAQ:OMCL) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.86)
Consensus Price Target: $51.57 (4.18% upside)

Analysts' Ratings History for Omnicell (NASDAQ:OMCL)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/5/2017Benchmark Co.Boost Price TargetBuy -> Buy$55.00 -> $67.00MediumView Rating Details
7/30/2017Piper Jaffray CompaniesReiterated RatingHold$40.00MediumView Rating Details
7/28/2017Dougherty & CoBoost Price TargetBuy$45.00 -> $49.00HighView Rating Details
7/28/2017Craig HallumBoost Price TargetBuy$46.00 -> $52.00HighView Rating Details
7/25/2017Cantor FitzgeraldReiterated RatingBuy$47.00MediumView Rating Details
4/26/2017CIBCBoost Price TargetOutperform$43.00 -> $53.00LowView Rating Details
4/25/2017Oppenheimer Holdings, Inc.Reiterated RatingOutperform$43.00 -> $53.00HighView Rating Details
9/8/2016SidotiDowngradeBuy -> Neutral$43.00N/AView Rating Details
7/29/2016FBR & CoBoost Price TargetOutperform$40.00 -> $41.00N/AView Rating Details
3/21/2016Topeka Capital MarketsLower Price TargetBuy$38.00 -> $37.00N/AView Rating Details
11/1/2015Cowen and CompanyReiterated RatingMarket Perform$37.00 -> $29.00N/AView Rating Details
(Data available from 9/25/2015 forward)


Earnings History for Omnicell (NASDAQ:OMCL)
Earnings by Quarter for Omnicell (NASDAQ:OMCL)
Earnings History by Quarter for Omnicell (NASDAQ OMCL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/25/2017$0.42N/AView Earnings Details
7/27/2017Q2 2017$0.02$0.02$174.08 million$180.90 millionViewN/AView Earnings Details
5/4/2017Q1 2017($0.30)$0.06$152.63 million$150.90 millionViewListenView Earnings Details
2/15/2017Q4 2016$0.41$0.37$179.28 million$171.97 millionViewListenView Earnings Details
10/27/2016Q316$0.41$0.40$179.75 million$179.40 millionViewListenView Earnings Details
7/28/2016Q216$0.32$0.38$170.89 million$175.60 millionViewListenView Earnings Details
4/28/2016Q116$0.26$0.35$167.18 million$171.00 millionViewListenView Earnings Details
2/4/2016Q415$0.39$0.40$126.89 million$130.30 millionViewListenView Earnings Details
10/29/2015Q315$0.36$0.36$128.50 million$125.20 millionViewListenView Earnings Details
7/30/2015Q215$0.32$0.28$121.35 million$112.80 millionViewListenView Earnings Details
4/30/2015Q115$0.23$0.29$112.00 million$16.20 millionViewN/AView Earnings Details
2/3/2015Q414$0.33$0.39$114.65 million$121.50 millionViewListenView Earnings Details
10/30/2014Q314$0.31$0.30$106.10 million$112.50 millionViewListenView Earnings Details
7/31/2014Q214$0.29$0.30$103.23 million$105.10 millionViewListenView Earnings Details
5/1/2014Q114$0.24$0.26$97.49 million$101.80 millionViewListenView Earnings Details
2/4/2014Q413$0.28$0.29$101.13 million$105.80 millionViewListenView Earnings Details
10/31/2013Q313$0.28$0.31$94.96 million$94.03 millionViewN/AView Earnings Details
8/1/2013Q2 2013$0.25$0.27$92.42 million$93.70 millionViewN/AView Earnings Details
5/2/2013Q1 2013$0.19$0.21$87.20 million$87.11 millionViewN/AView Earnings Details
1/31/2013Q4 2012$0.25$0.25$87.31 million$90.16 millionViewN/AView Earnings Details
10/25/2012$0.22$0.29ViewN/AView Earnings Details
8/1/2012$0.18$0.20ViewN/AView Earnings Details
5/2/2012$0.13$0.13ViewN/AView Earnings Details
1/26/2012$0.16$0.19ViewN/AView Earnings Details
10/27/2011$0.16$0.16ViewN/AView Earnings Details
7/28/2011$0.13$0.15ViewN/AView Earnings Details
5/2/2011$0.10$0.11ViewN/AView Earnings Details
1/27/2011$0.12$0.11ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Omnicell (NASDAQ:OMCL)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20171$0.12$0.12$0.12
Q4 20171$0.32$0.32$0.32
(Data provided by Zacks Investment Research)


Dividend History for Omnicell (NASDAQ:OMCL)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Omnicell (NASDAQ:OMCL)
Insider Ownership Percentage: 3.77%
Institutional Ownership Percentage: 96.35%
Insider Trades by Quarter for Omnicell (NASDAQ:OMCL)
Institutional Ownership by Quarter for Omnicell (NASDAQ:OMCL)
Insider Trades by Quarter for Omnicell (NASDAQ:OMCL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/15/2017Robin Gene SeimEVPSell9,780$48.97$478,926.60View SEC Filing  
9/5/2017Gary S. PetersmeyerDirectorSell1,000$51.73$51,730.00View SEC Filing  
9/1/2017Randall A. LippsChairmanSell10,625$52.00$552,500.00View SEC Filing  
8/18/2017Dan S JohnstonEVPSell16,400$48.86$801,304.00View SEC Filing  
8/15/2017Robin Gene SeimEVPSell15,109$50.86$768,443.74View SEC Filing  
8/9/2017Peter J KuipersVPSell18,054$50.31$908,296.74View SEC Filing  
8/8/2017J Christopher DrewVPSell11,375$51.16$581,945.00View SEC Filing  
8/7/2017Jorge R TaborgaVPSell20,719$50.98$1,056,254.62View SEC Filing  
8/1/2017Randall A LippsChairmanSell40,000$49.76$1,990,400.00View SEC Filing  
7/28/2017Randall A LippsChairmanSell37,500$46.00$1,725,000.00View SEC Filing  
6/19/2017Randall A LippsChairmanSell31,527$42.87$1,351,562.49View SEC Filing  
6/5/2017Randall A LippsChairmanSell9,900$43.00$425,700.00View SEC Filing  
5/26/2017James T JudsonDirectorSell12,148$41.50$504,142.00View SEC Filing  
5/25/2017Gary S PetersmeyerDirectorSell2,200$41.41$91,102.00View SEC Filing  
5/19/2017Dan S JohnstonEVPSell16,400$40.67$666,988.00View SEC Filing  
5/9/2017J Christopher DrewVPSell10,625$40.97$435,306.25View SEC Filing  
4/25/2017Randall A LippsChairmanSell18,200$41.00$746,200.00View SEC Filing  
3/10/2017Gary S PetersmeyerDirectorSell2,658$37.45$99,542.10View SEC Filing  
2/21/2017Sara J WhiteDirectorSell3,443$38.06$131,040.58View SEC Filing  
11/18/2016Dan S JohnstonEVPSell8,850$33.65$297,802.50View SEC Filing  
11/18/2016Jorge R TaborgaVPSell2,068$33.66$69,608.88View SEC Filing  
11/8/2016J Christopher DrewVPSell20,000$31.95$639,000.00View SEC Filing  
9/12/2016Gary S PetersmeyerDirectorSell2,000$37.98$75,960.00View SEC Filing  
9/8/2016Gary S PetersmeyerDirectorSell2,400$39.39$94,536.00View SEC Filing  
9/6/2016Gary S PetersmeyerDirectorSell2,000$39.02$78,040.00View SEC Filing  
9/2/2016Gary S PetersmeyerDirectorSell3,000$38.52$115,560.00View SEC Filing  
8/19/2016Dan S JohnstonEVPSell8,850$36.93$326,830.50View SEC Filing  
8/19/2016Jorge R TaborgaVPSell1,778$36.92$65,643.76View SEC Filing  
8/11/2016Randall A LippsChairmanSell37,425$37.37$1,398,572.25View SEC Filing  
8/9/2016J Christopher DrewVPSell15,000$37.89$568,350.00View SEC Filing  
8/9/2016James T JudsonDirectorSell6,250$37.98$237,375.00View SEC Filing  
8/4/2016Gary S PetersmeyerDirectorSell8,750$37.84$331,100.00View SEC Filing  
7/29/2016Jorge R TaborgaVPSell10,023$40.00$400,920.00View SEC Filing  
7/6/2016Robin Gene SeimEVPSell5,302$34.75$184,244.50View SEC Filing  
7/1/2016Robin Gene SeimEVPSell3,645$35.00$127,575.00View SEC Filing  
6/6/2016Jorge R TaborgaVPSell25,979$33.00$857,307.00View SEC Filing  
5/24/2016Gary S PetersmeyerDirectorSell6,250$31.22$195,125.00View SEC Filing  
5/20/2016Dan S JohnstonEVPSell8,850$30.73$271,960.50View SEC Filing  
5/20/2016Jorge R TaborgaVPSell1,933$30.73$59,401.09View SEC Filing  
5/10/2016J Christopher DrewVPSell15,000$31.63$474,450.00View SEC Filing  
5/5/2016Sara J WhiteDirectorSell2,000$31.76$63,520.00View SEC Filing  
4/29/2016Robin Gene SeimEVPSell6,407$31.00$198,617.00View SEC Filing  
4/26/2016Jorge R TaborgaVPSell23,827$30.00$714,810.00View SEC Filing  
4/26/2016Robin Gene SeimEVPSell767$30.00$23,010.00View SEC Filing  
2/19/2016Dan S JohnstonEVPSell8,850$27.41$242,578.50View SEC Filing  
2/19/2016Jorge R TaborgaVPSell1,685$27.42$46,202.70View SEC Filing  
2/11/2016Randall A. LippsCEOSell40,000$27.81$1,112,400.00View SEC Filing  
2/9/2016J Christopher DrewVPSell15,000$27.57$413,550.00View SEC Filing  
12/18/2015Nhat H. NgoVPSell4,069$28.71$116,820.99View SEC Filing  
11/17/2015Dan S. JohnstonVPSell2,500$28.00$70,000.00View SEC Filing  
11/10/2015J Christopher DrewVPSell25,000$26.79$669,750.00View SEC Filing  
11/9/2015Dan S. JohnstonVPSell2,700$27.29$73,683.00View SEC Filing  
10/13/2015Gary S. PetersmeyerDirectorSell670$31.66$21,212.20View SEC Filing  
8/13/2015Robin Gene SeimCFOSell23,946$35.63$853,195.98View SEC Filing  
7/1/2015Robin Gene SeimCFOSell19,582$37.84$740,982.88View SEC Filing  
6/17/2015Nhat H NgoVPSell4,067$38.78$157,718.26View SEC Filing  
6/2/2015James T JudsonDirectorSell8,032$36.83$295,818.56View SEC Filing  
6/2/2015Nhat H NgoVPSell6,375$36.80$234,600.00View SEC Filing  
5/26/2015Sara J WhiteDirectorSell4,000$36.25$145,000.00View SEC Filing  
5/7/2015Dan S JohnstonVPSell7,715$34.25$264,238.75View SEC Filing  
2/12/2015J Christopher DrewVPSell25,000$34.62$865,500.00View SEC Filing  
2/6/2015Dan S JohnstonVPSell6,552$33.29$218,116.08View SEC Filing  
2/2/2015James T JudsonDirectorSell5,000$31.61$158,050.00View SEC Filing  
1/13/2015Gary S PetersmeyerDirectorSell670$31.31$20,977.70View SEC Filing  
1/2/2015James T JudsonDirectorSell5,000$32.36$161,800.00View SEC Filing  
1/2/2015Robin Gene SeimCFOSell1,948$32.36$63,037.28View SEC Filing  
12/17/2014Marga Ortigas-WedekindVPSell4,080$32.20$131,376.00View SEC Filing  
12/15/2014Gary S PetersmeyerDirectorSell670$33.25$22,277.50View SEC Filing  
12/8/2014Nhat H NgoVPSell1,754$32.89$57,689.06View SEC Filing  
12/1/2014James T JudsonDirectorSell5,000$31.94$159,700.00View SEC Filing  
11/12/2014Randy D LindholmDirectorSell5,000$31.72$158,600.00View SEC Filing  
11/11/2014J Christopher DrewVPSell37,500$31.86$1,194,750.00View SEC Filing  
11/7/2014Dan S JohnstonVPSell27,625$31.74$876,817.50View SEC Filing  
11/3/2014James T JudsonDirectorSell5,000$32.27$161,350.00View SEC Filing  
10/3/2014Nhat H NgoVPSell2,275$28.00$63,700.00View SEC Filing  
10/1/2014James T JudsonDirectorSell5,000$27.02$135,100.00View SEC Filing  
9/15/2014Jorge R TaborgaVPSell944$26.37$24,893.28View SEC Filing  
9/15/2014Robin Gene SeimCFOSell9,347$26.32$246,013.04View SEC Filing  
9/2/2014James T JudsonDirectorSell5,000$28.18$140,900.00View SEC Filing  
9/2/2014Robin Gene SeimCFOSell27,500$28.19$775,225.00View SEC Filing  
8/26/2014Dan S JohnstonVPSell6,250$28.00$175,000.00View SEC Filing  
8/26/2014James T JudsonDirectorSell9,913$27.91$276,671.83View SEC Filing  
7/9/2014Robin Gene SeimCFOSell2,442$28.21$68,888.82View SEC Filing  
7/1/2014James T JudsonDirectorSell5,000$29.28$146,400.00View SEC Filing  
6/26/2014Marga Ortigas-WedekindVPSell2,961$28.17$83,411.37View SEC Filing  
6/25/2014Nhat H NgoVPSell2,274$28.00$63,672.00View SEC Filing  
6/17/2014Nhat H NgoVPSell1,420$27.70$39,334.00View SEC Filing  
6/10/2014Nhat H NgoVPSell1,964$26.38$51,810.32View SEC Filing  
6/2/2014Gary S PetersmeyerDirectorSell5,000$26.45$132,250.00View SEC Filing  
5/21/2014Gary PetersmeyerDirectorSell2,000$26.51$53,020.00View SEC Filing  
5/13/2014J Christopher DrewVPSell37,500$26.08$978,000.00View SEC Filing  
5/7/2014Dan JohnstonVPSell4,000$25.25$101,000.00View SEC Filing  
5/1/2014James JudsonDirectorSell5,000$26.24$131,200.00View SEC Filing  
4/8/2014Nhat NgoVPSell1,002$27.40$27,454.80View SEC Filing  
3/18/2014Marga Ortigas-WedekindVPSell5,880$30.00$176,400.00View SEC Filing  
3/18/2014Randall LippsCEOSell124,910$29.89$3,733,559.90View SEC Filing  
12/18/2013Nhat NgoVPSell1,462$24.43$35,716.66View SEC Filing  
12/18/2013Randall LippsCEOSell64,739$24.30$1,573,157.70View SEC Filing  
12/3/2013Dan JohnstonVPSell73,419$23.24$1,706,257.56View SEC Filing  
11/11/2013Randy LindholmDirectorSell3,587$23.00$82,501.00View SEC Filing  
11/7/2013Dan JohnstonVPSell8,000$22.99$183,920.00View SEC Filing  
10/23/2013Robin Gene SeimCFOSell7,664$24.50$187,768.00View SEC Filing  
10/21/2013Robin Gene SeimCFOSell9,349$23.76$222,132.24View SEC Filing  
10/1/2013James T JudsonDirectorSell5,000$23.66$118,300.00View SEC Filing  
9/24/2013Randall LippsCEOSell68,204$25.00$1,705,100.00View SEC Filing  
9/23/2013Marga Ortigas-WedekindVPSell4,000$25.00$100,000.00View SEC Filing  
9/23/2013Randall LippsCEOSell5,083$25.00$127,075.00View SEC Filing  
9/20/2013Robin Gene SeimCFOSell27,500$24.35$669,625.00View SEC Filing  
9/18/2013Randall LippsCEOSell64,453$23.67$1,525,602.51View SEC Filing  
9/4/2013Nhat H NgoVPSell7,362$24.00$176,688.00View SEC Filing  
9/3/2013James JudsonDirectorSell5,000$22.77$113,850.00View SEC Filing  
8/20/2013James JudsonDirectorSell11,724$22.74$266,603.76View SEC Filing  
8/13/2013J Christopher DrewVPSell20,000$22.83$456,600.00View SEC Filing  
8/12/2013Donald WegmillerDirectorSell34,976$22.87$799,901.12View SEC Filing  
8/7/2013Dan JohnstonVPSell8,000$22.92$183,360.00View SEC Filing  
8/6/2013Randall LippsCEOSell5,321$23.00$122,383.00View SEC Filing  
8/2/2013Randall A LippsCEOSell25,000$22.50$562,500.00View SEC Filing  
8/1/2013James JudsonDirectorSell5,000$21.00$105,000.00View SEC Filing  
7/19/2013Nhat H NgoVPSell41,875$21.00$879,375.00View SEC Filing  
7/19/2013Randall A LippsCEOSell5,080$21.00$106,680.00View SEC Filing  
7/1/2013James T JudsonDirectorSell5,000$20.46$102,300.00View SEC Filing  
7/1/2013Robin Gene SeimCFOSell13,032$20.42$266,113.44View SEC Filing  
6/28/2013Marga Ortigas-WedekindVPSell4,545$20.00$90,900.00View SEC Filing  
6/28/2013Randall A LippsCEOSell25,000$20.00$500,000.00View SEC Filing  
6/21/2013Nhat H NgoVPSell3,459$19.01$65,755.59View SEC Filing  
6/18/2013Randall A LippsCEOSell66,378$19.10$1,267,819.80View SEC Filing  
6/10/2013Randy D LindholmDirectorSell23,901$19.14$457,465.14View SEC Filing  
6/4/2013Robin Gene SeimCFOSell25,000$18.72$468,000.00View SEC Filing  
5/22/2013Gary S PetersmeyerDirectorSell2,750$18.10$49,775.00View SEC Filing  
5/16/2013J Christopher DrewVPSell26,000$18.69$485,940.00View SEC Filing  
5/14/2013J Christopher DrewVPSell26,000$18.45$479,700.00View SEC Filing  
5/10/2013Sara J WhiteDirectorSell7,200$18.50$133,200.00View SEC Filing  
5/7/2013Dan S JohnstonVPSell8,000$18.44$147,520.00View SEC Filing  
12/3/2012Gary S PetersmeyerDirectorSell1,359$15.17$20,616.03View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Omnicell (NASDAQ:OMCL)
Latest Headlines for Omnicell (NASDAQ:OMCL)
DateHeadline logoOmnicell, Inc. breached its 50 day moving average in a Bearish Manner : OMCL-US : September 20, 2017 - September 22 at 7:20 AM logoOmnicell, Inc. – Value Analysis (NASDAQ:OMCL) : September 21, 2017 - September 22 at 7:20 AM logo$191.88 Million in Sales Expected for Omnicell, Inc. (OMCL) This Quarter - September 19 at 12:02 PM logoOmnicell, Inc. (OMCL) EVP Robin Gene Seim Sells 9,780 Shares - September 15 at 7:44 PM logoAnalyzing Omnicell (OMCL) & Its Rivals - September 14 at 10:22 PM logoOmnicell (OMCL) versus Evolent Health (EVH) Critical Contrast - September 14 at 12:26 AM logoContrasting Omnicell (OMCL) and its Rivals - September 10 at 6:26 PM logoOmnicell, Inc. (OMCL) Price Target Raised to $67.00 at Benchmark Co. - September 6 at 12:52 AM logoOmnicell, Inc. (OMCL) Director Sells $51,730.00 in Stock - September 5 at 8:32 PM logoHead-To-Head Review: Omnicell (OMCL) vs. Press Ganey Holdings (PGND) - September 2 at 8:28 PM logoOmnicell, Inc. (OMCL) Receives Average Recommendation of "Buy" from Brokerages - September 2 at 2:40 PM logoInsider Selling: Omnicell, Inc. (OMCL) Chairman Sells 10,625 Shares of Stock - September 1 at 7:42 PM logoOmnicell To Present At The 12th Annual Wells Fargo Securities Healthcare Conference - August 31 at 8:13 AM logoOmnicell, Inc. (OMCL) Expected to Post Earnings of $0.41 Per Share - August 29 at 6:18 PM logoAnalyzing Omnicell (OMCL) and Allscripts Healthcare Solutions (MDRX) - August 22 at 2:10 AM logoDan S. Johnston Sells 16,400 Shares of Omnicell, Inc. (OMCL) Stock - August 18 at 7:46 PM logoHead to Head Survey: Omnicell (OMCL) versus Fluidigm (FLDM) - August 17 at 12:20 PM logoOmnicell Announces Enhancements to its Patient Management Access Portal (PMAP) for Improved Patient Adherence and Pharmacy Workflow - August 17 at 6:31 AM logoOmnicell, Inc. (OMCL) EVP Robin Gene Seim Sells 15,109 Shares - August 16 at 7:59 PM logoOmnicell, Inc. (NASDAQ:OMCL) Expected to Announce Quarterly Sales of $191.90 Million - August 13 at 7:56 AM logoZacks: Analysts Expect Omnicell, Inc. (OMCL) to Post $0.20 EPS - August 11 at 4:46 PM logoOmnicell, Inc. (NASDAQ:OMCL) VP Peter J. Kuipers Sells 18,054 Shares - August 9 at 10:20 PM logoOmnicell, Inc. (NASDAQ:OMCL) VP Sells $581,945.00 in Stock - August 9 at 8:22 PM logoOmnicell, Inc. (OMCL) VP Sells $1,056,254.62 in Stock - August 8 at 7:44 PM logoOmnicell, Inc. (NASDAQ:OMCL) Receives Consensus Rating of "Buy" from Analysts - August 8 at 2:44 PM logoVeeva Systems (VEEV) & Omnicell (OMCL) Head to Head Survey - August 5 at 8:30 AM logoComparing Allscripts Healthcare Solutions (MDRX) & Omnicell (NASDAQ:OMCL) - August 2 at 10:14 PM logoInsider Selling: Omnicell, Inc. (NASDAQ:OMCL) Chairman Sells 40,000 Shares of Stock - August 1 at 7:28 PM logoReviewing Castlight Health, inc. (CSLT) and Omnicell (NASDAQ:OMCL) - July 31 at 12:34 AM logoOmnicell, Inc. (OMCL) Receives Hold Rating from Piper Jaffray Companies - July 30 at 11:36 AM logoOmnicell Inc. (OMCL) Has Surged To A New High After Q2 Report - July 29 at 6:02 AM logoRandall A. Lipps Sells 37,500 Shares of Omnicell, Inc. (NASDAQ:OMCL) Stock - July 28 at 7:11 PM logoOmnicell, Inc. (OMCL) PT Raised to $49.00 - July 28 at 12:25 PM logoOmnicell, Inc. (NASDAQ:OMCL) PT Raised to $52.00 - July 28 at 9:12 AM logoOmnicell Achieves Record Revenue in the Second Quarter 2017 - July 28 at 6:28 AM logoEdited Transcript of OMCL earnings conference call or presentation 27-Jul-17 8:30pm GMT - July 28 at 6:28 AM logoOmnicell tops Street 2Q forecasts - July 28 at 6:28 AM logoOmnicell, Inc. (OMCL) Updates FY17 Earnings Guidance - July 28 at 12:21 AM logoOmnicell, Inc. (NASDAQ:OMCL) Releases Q3 Earnings Guidance - July 28 at 12:21 AM logoOmnicell, Inc. (OMCL) Posts Quarterly Earnings Results, Beats Estimates By $0.08 EPS - July 27 at 9:21 PM logoGreater Hudson Valley Health System Adds New XT Series to Expand Omnicell Partnership - July 27 at 6:05 AM logoOmnicell, Inc. (OMCL) Expected to Announce Quarterly Sales of $173.85 Million - July 26 at 3:53 PM logoWhite River Health System Selects Omnicell's Medication Management Solutions for Patient Safety and Long-Term Success - July 26 at 6:04 AM logoOmnicell, Inc. (OMCL) Rating Reiterated by Cantor Fitzgerald - July 25 at 10:13 PM logoCritical Comparison: Simulations Plus (SLP) versus Omnicell (OMCL) - July 24 at 8:22 PM logoOmnicell Launches XT Series Automated Dispensing Cabinets for Supply Management - July 24 at 2:24 PM logoOmnicell to Release Second Quarter 2017 Earnings Results on July 27, 2017 - July 22 at 7:18 AM logoOmnicell, Inc. (NASDAQ:OMCL) Given Average Rating of "Buy" by Brokerages - July 14 at 3:18 PM logoETFs with exposure to Omnicell, Inc. : July 10, 2017 - July 11 at 6:21 AM logoOmnicell, Inc. (NASDAQ:OMCL) Rating Increased to Hold at Zacks Investment Research - July 4 at 1:07 PM



Omnicell (OMCL) Chart for Monday, September, 25, 2017

This page was last updated on 9/25/2017 by Staff